Skip to main content
SpringerLink
Log in

Management of Neuroendocrine Tumors

  • Chapter
  • First Online:
PET/CT in Neuroendocrine Tumors

Part of the book series: Clinicians’ Guides to Radionuclide Hybrid Imaging ((PET/CT))

Abstract

In neuroendocrine neoplasms (NENs), radical surgical resection represents the only really curative treatment in patients with resectable locally advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–73.

    Article  CAS  PubMed  Google Scholar 

  2. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.

    Article  CAS  PubMed  Google Scholar 

  3. Caplin M, Phan A, Liyanage N, et al. Lanreotide autogel (depot) significantly improves tumor progression-free survival in patients with non-functioning Gastroenteropancreatic Neuroendocrine Tumors: Results of the CLARINET Study. European Cancer Congress. Abstract 3. Presented 28 Sept 2013; 2013.

    Google Scholar 

  4. Yao JC, Shah MH, Ito T, et al. RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) study group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.

    Google Scholar 

  5. Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  6. Pavel ME, Hainsworth JD, Baudin E. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    Article  CAS  PubMed  Google Scholar 

  7. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moertel CG, Kvols LK, O’Connel MJ. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer. 1991;68:227–32.

    Article  CAS  PubMed  Google Scholar 

  9. Kwekkeboom DJ, van de Herder W, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] Octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  CAS  PubMed  Google Scholar 

  10. Sansovini M, Severi S, Ambrosetti A, et al. Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology. 2013;97(4):347–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, Milan, Italy

    Nicola Fazio & Francesca Spada

Authors
  1. Nicola Fazio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Spada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Fazio .

Editor information

Editors and Affiliations

  1. S.Orsola-Malpighi University Hospital, Nuclear Medicine, DIMES, Bologna, Bologna, Italy

    Valentina Ambrosini

  2. Department of Nuclear Medicine, S.Orsola-Malpighi Hospital, Bologna, Bologna, Italy

    Stefano Fanti

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fazio, N., Spada, F. (2016). Management of Neuroendocrine Tumors. In: Ambrosini, V., Fanti, S. (eds) PET/CT in Neuroendocrine Tumors. Clinicians’ Guides to Radionuclide Hybrid Imaging(). Springer, Cham. https://doi.org/10.1007/978-3-319-29203-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29203-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29202-1

  • Online ISBN: 978-3-319-29203-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation